Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Discussion: There were 8 mutations in the RT region, rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V and rtM309K that were significantly associated with the progression of HCC in treatment-naive patients.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Result: In this study, non-classical mutations were observed in 29 patients who suffering from virological breakthrough and without classical mutations (Table 4) at 9 sites (V191I, V207I/M, S213T, E218D, F221Y, I224V, L229V, N/H238 and R242D).
Result: Interestingly, mutation pattern of A181T associated to F221Y was detected after 22 months of TDF monotherapy with virological and biochemical breakthrough in case two.
Result: Out of 24 mutations of L229 (Table 3), 18 were associated to M204I or V; 2 coexisted with F221Y (Table 4); 2 were associated to
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Abstract: Eight mutations in RT (rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K) are significantly associated with HCC progression.
Method: A total of 26 types of RT mutations, including rtS
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.
Introduction: Virological breakthrough on TDF therapy has been reported in two patients harbouring rtS78T/sC69 mutations, and in another patient with multi-site polymerase mutations; rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and
F221Y mutation in hepatitis B virus reverse transcriptase is associated with hepatocellular carcinoma prognosis following liver resection.
Abstract: rtF221Y was also an independent risk factor for poor overall survival rates (HR=2.557; 95% CI, 1.344-4.866; P=0.004).
Abstract: As a result, rtF221Y was identified as a risk factor for poor prognosis and may be a potential viral marker for predicting prognosis in HCC.
Abstract: The rtF221Y variation and a tumor size >8 cm were found to be independent risk factors for the postoperative recurrence of HCC, with hazard ratios of 2.345 (95% CI, 1.391-3.953; P=0.001) and 1.838 (95% CI, 1.069-3.161; P=0.028), respectively.
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Abstract: T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies.
Result: F221Y/S was highest in groups I and IV, at 25 and 19.2%, respectively.
Result: Group I: In addition to the nine amino acid substitutions that related to LAM resistance, F221Y/S, which is related to ADV resistance, also was found in the patients in this group, who only received LAM (Table 2).
Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.
PMID: 24630522
2014
Diagnostic microbiology and infectious disease
Abstract: However, NAr mutations found in 6 isolates (37.5%) involved 7 positions including rtL91I, rtT128I, rtQ215P, rtF221Y, rtN238D, rtC256S, and rtI266G.
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
Abstract: However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and rtV191I combined mutations without rtA194T mutation.
Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma.
Result: The L213I mutation (TTA to ATG) in surface leads to F221Y and A222T dual mutations in reverse transcriptase (RT) domain of HBV polymerase resulting a change in polymerase activity or viral replication whereas the mutation S98T in pre S1 (L12V in Polymerase) lies in the non-essential spacer region of the polymerase.
Table: F221Y
Discussion: One point mutation L213I observed in the overlapping surface and
Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine.
HBV mutation literature information.
PMID: 
2021
Molecular and clinical oncology
Browser Board
Co-occurred Entities
Filtrator
ViMRT